Endexx Initiates Adaptive Clinical Study With Proprietary CBD Capsule Formulation To Address Neuropathic Pain
Endexx Initiates Adaptive Clinical Study With Proprietary CBD Capsule Formulation to Address Neuropathic Pain
Endexx Corporation (OTC PINK: EDXC), a provider of innovative hemp derived phyto-nutrients and nutritional products, has announced the launch of a doctor supervised, adaptive clinical study to test the efficacy of its proprietary CBD capsule in response to patients suffering from neuropathic pain.
Dr. Martin Pressman, DPM in New Haven, Connecticut, Dr. Daniel Brandwein, DPM in Weston, Florida, Dr. Michael Horwitz, DPM and Dr. Daniel Kiddy, DPM, both in St Louis, Missouri will enroll twenty patients into four groups, for a one month study using CBD enriched capsules to evaluate neuropathic pain reduction.
The proprietary formulations are pharmacist formulated and manufactured capsules which include a dual pack as a day and night formula with cannabidiol as its primary active ingredient. Each patient will be taking two capsules a day with results to be monitored. At the end of the study, findings will be subjected to an independent peer review board.
This study is an extension of the work conducted by Dr. Kiddy with his patients and a follow up of Dr. Brandwein’s research that demonstrated an average pain reduction after 2 weeks of usage from 7 to 8 down to 3 to 4 on a pain scale of 1 to 10, using 4 to 5 drops of CBD-rich hemp oil twice a day.
Dr. Brandwein stated, “I am very excited about the upcoming new trial where we can follow the information even closer. I also believe that in a capsule form, patients will be more compliant and have better results. In some cases, my patients have decreased and discontinued their usage of Neurontin and Gabapentin.”